AJP - Endo Track the topics, authors and articles important to you
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Endocrinol Metab 295: E225-E226, 2008. First published May 6, 2008; doi:10.1152/ajpendo.90406.2008
0193-1849/08 $8.00
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
295/2/E225    most recent
90406.2008v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schürmann, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schürmann, A.

EDITORIAL FOCUS

Insight into the "odd" hexose transporters GLUT3, GLUT5, and GLUT7

Annette Schürmann

Department of Pharmacology, German Institute of Human Nutrition, Potsdam-Rehbruecke, Germany

GLUCOSE TRANSPORT FACILITATORS (GLUT proteins) mediate the transport of glucose and other monosaccharides into and out of mammalian cells and therefore play a pivotal role in maintaining blood glucose concentrations in a normal range between 4.5 and 6 mM (14). In addition, GLUT proteins are involved in the glucose-sensing machinery; e.g., in pancreatic β-cells, GLUT2 participates in the regulation of glucose-stimulated insulin secretion. Screening the literature results in a large number of publications on the insulin-regulated glucose transporter GLUT4 (7, 8), which is without question, together with GLUT2, a prominent transporter required for maintenance of glucose homeostasis and affected in diseases such as obesity and type 2 diabetes. However, since the late 1990s, we have known that the whole family of human GLUT proteins consists of 14 members (9, 14, 17, 18), indicating that glucose delivery into cells is a process of considerable complexity. The various transporters exhibit different substrate specificities, kinetic properties, and tissue expression profiles (Fig. 1). The fact that certain tissues and cells express two or even more glucose transporter isoforms indicates that the organism developed a backup system assuring adequate energy supply. For instance, spermatozoa and their precursor cells express several transporters: GLUT3, -5, -8, and -9, which guarantees fuel supply and function of spermatozoa even when hexose transport via one of the GLUT proteins is impaired.


Figure 1
View larger version (17K):
[in this window]
[in a new window]

 
Fig. 1. Dendrogram of the family of human hexose transporters and major sites of expression (see Ref. 14). Numbers at the branches of the tree indicate percentage of identity.

 
A series of minireviews in this issue on facilitative hexose transporters summarizes earlier and recent developments defining the specific roles of GLUT3, GLUT5, and GLUT7 in normal and morbid states. GLUT3 is a high-affinity glucose transporter, GLUT5 is a specific fructose transporter, while GLUT7 transports both glucose and fructose with high affinity.

Glucose is the obligate energetic source for the mammalian brain, and it is assumed that the majority of cerebral glucose utilization fuels neuronal activity via oxidative metabolism (15). GLUT1 is located in the microvascular endothelial cells of the blood-brain barrier and delivers glucose from the circulation to the brain, and GLUT3 mediates glucose transport into neurons. However, GLUT3 is also expressed in other cells (sperm and pre- and postimplantaion embryo, circulating white blood cells, and carcinoma cells) where it triggers the specific requirements for glucose. The review by Simpson et al. (16) discusses the properties for GLUT3, its expression, subcellular distribution, and regulation and focuses on features that make GLUT3 unique within the GLUT family.

GLUT5 is the best-characterized fructose transporter and is expressed in several cell types and tissues (intestine, testis, kidney, skeletal muscle, fat, and brain). These days, GLUT5 is of tremendous interest because total fructose consumption has increased dramatically, e.g., in the United States from ~20 to ~80 g/day in the last 20–30 years (2). Increased fructose consumption, in particular as carbonated beverages, has been attributed to participate in the increased prevalence of obesity and type 2 diabetes. Fructose is absorbed in the jejunum and transferred (13) through the apical membrane of epithelial cells into the portal circulation (3). In the liver, fructose is phosphorylated to fructose 1-phosphate and converted to glycerol 3-phosphate for the synthesis of glycerol (6) or metabolized to acetyl-CoA and incorporated into fatty acids, while only a small portion is converted into glucose (1). Therefore, the preferential entry of fructose into lipogenesis might contribute to the effects of fructose to induce hyperlipidemia and to increased serum triglyceride levels (10). Several members of the GLUT family are able to transport fructose (GLUT2, -5, -7, -8, -9, -11, and -12), but only GLUT5 exclusively transports fructose. The review by Dourard and Ferraris (5) focuses on alterations of GLUT5 expression and fructose uptake in diabetes, hypertension, obesity, and inflammation. It also gives important information on the role of GLUT5 during intestine development, metabolic disturbances, and cancer.

A closely related protein of GLUT5 is GLUT7, bearing 53% identity. It is a high-affinity transporter for glucose and fructose and is mainly expressed in the brush-border membrane of the small intestine and in the colon (11). Other intestinal glucose transporters, SGLT1, GLUT2, and GLUT5 are expressed in the jejunum, whereas the distribution of GLUT7 is limited to the distal region of the small intestine, the ileum, which does not contain high concentrations of glucose and fructose. This observation suggested that GLUT7 does not play a major role in taking up glucose and fructose from the diet but that it may be important toward the end of a meal when luminal concentrations of hexoses in the ileum are low (11). Comparison of sequence alignments and mutation studies on GLUT7 identified a specific hydrophobic residue in transmembrane domain 7 that determines the specificity for fructose (12). Several mutational studies mainly performed in GLUT1 and GLUT4 lead to the concept that GLUT proteins undergo specific conformational changes during the passage of the hexose. It is believed that its binding to the outward-facing binding site induces a conformational alteration that moves the substrate through the pore of the GLUT protein. Thereafter, the substrate is released from the inward-facing binding site to the cytoplasm, and the transporter undergoes the reverse conformational change (9). The review on GLUT7 by C. Cheeseman (4), who discovered GLUT7 as the latest member of the GLUT family, introduces the hypothesis that GLUT proteins may have a selectivity filter at the exofacial site which helps to determine which substrate is transported.

FOOTNOTES


Address for reprint requests and other correspondence: A. Schürmann, Dept. of Pharmacology, German Institute of Human Nutrition, Potsdam-Rehbruecke, Arthur-Scheunert-Allee 114-116, D-14558 Nuthetal, Germany (e-mail: schuermann{at}dife.de)

REFERENCES

  1. Aoyama Y, Yoshida A, Ashida K. Effect of dietary fats and fatty acids on the liver lipid accumulation induced by feeding a protein-repletion diet containing fructose to protein-depleted rats. J Nutr 104: 741–746, 1974.[Abstract/Free Full Text]
  2. Bray GA. How bad is fructose? Am J Clin Nutr 86: 895–896, 2007.[Free Full Text]
  3. Busserolles J, Gueux E, Rock E, Mazur A, Rayssiguier Y. Substituting honey for refined carbohydrates protects rats from hypertriglyceridemic and prooxidative effects of fructose. J Nutr 132: 3379–3382, 2002.[Abstract/Free Full Text]
  4. Cheeseman CI. GLUT7, a class II high-affinity intestinal glucose/fructose facilitated hexose transporter. Am J Physiol Endocrinol Metab (May 13, 2008); doi:10.1152/ajpendo.90394.2008.[Abstract/Free Full Text]
  5. Douard V, Ferraris RP. Regulation of the fructose transporter GLUT5 in health and disease. Am J Physiol Endocrinol Metab (April 8, 2008); doi:10.1152/ajpendo.90245.2008.[Abstract/Free Full Text]
  6. Frayn KN, Kingman SM. Dietary sugars and lipid metabolism in humans. Am J Clin Nutr 62, Suppl 1: 250S–261S, 1995.[Medline]
  7. Hou JC, Pessin JE. Ins (endocytosis) and outs (exocytosis) of GLUT4 trafficking. Curr Opin Cell Biol 19: 466–73, 2007.[CrossRef][Web of Science][Medline]
  8. Huang S, Czech MP. The GLUT4 glucose transporter. Cell Metab 5: 237–252, 2007.[CrossRef][Web of Science][Medline]
  9. Joost HG, Thorens B. The extended GLUT-family of sugar/polyol transport facilitators: nomenclature, sequence characteristics, and potential function of its novel members. Mol Membr Biol 18: 247–256, 2001.[CrossRef][Web of Science][Medline]
  10. Jürgens H, Haass W, Castañeda TR, Schürmann A, Koebnick C, Dombrowski F, Otto B, Nawrocki AR, Scherer PE, Spranger J, Ristow M, Joost HG, Havel PJ, Tschöp MH. Consuming fructose-sweetened beverages increases body adiposity in mice. Obes Res 13: 1146–1156, 2005.[Web of Science][Medline]
  11. Li Q, Manolescu A, Ritzel M, Yao S, Slugoski M, Young JD, Chen XZ, Cheeseman CI. Cloning and functional characterization of the human GLUT7 isoform SLC2A7 from the small intestine. Am J Physiol Gastrointest Liver Physiol 287: G236–G242, 2004.[Abstract/Free Full Text]
  12. Manolescu A, Salas-Burgos AM, Fischbarg J, Cheeseman CI. Identification of a hydrophobic residue as a key determinant of fructose transport by the facilitative hexose transporter SLC2A7 (GLUT7). J Biol Chem 280: 42978–42983, 2005.[Abstract/Free Full Text]
  13. Riby JE, Fujisawa T, Kretchmer Fructose absorption N. Am J Clin Nutr 58, Suppl 5: 748S–753S, 1993.[Medline]
  14. Scheepers A, Joost HG, Schürmann A. The glucose transporter families SGLT and GLUT: molecular basis of normal and aberrant function. J Parenter Enteral Nutr 28: 364–371, 2004.[Abstract/Free Full Text]
  15. Simpson IA, Carruthers A, Vannucci SJ. Supply and demand in cerebral energy metabolism: the role of nutrient transporters. J Cereb Blood Flow Metab 27: 1766–1791, 2007.[CrossRef][Web of Science][Medline]
  16. Simpson IA, Dwyer D, Malide D, Moley KH, Travis A, Vannucci SJ. The facilitative glucose transporter GLUT3: 20 years of distinction. Am J Physiol Endocrinol Metab (June 24, 2008); doi:10.1152/ajpendo.90388.2008.[Abstract/Free Full Text]
  17. Uldry M, Thorens B. The SLC2 family of facilitated hexose and polyol transporters. Pflügers Arch 447: 480–489, 2004.[CrossRef][Web of Science][Medline]
  18. Wood IS, Trayhurn P. Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins. Br J Nutr 89: 3–9, 2003.[Web of Science][Medline]




This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
295/2/E225    most recent
90406.2008v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schürmann, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schürmann, A.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2008 by the American Physiological Society.